PolyActiva has announced the next important milestone of our transformational growth - the appointment of seasoned biopharmaceutical executive, Jerry St. Peter, as CEO and Board Director of PolyActiva, following the…

PolyActiva has recently secured $40 million (AUD) in Series C funding, led by the Australian National Reconstruction Fund (NRFC), and Australia's leading biotech investor, Brandon Capital. The funds will support…

PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients. Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks,…

PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily…

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients. The interim Phase 2a results demonstrate a sustained >20% reduction of IOP…

PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022

PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.

PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.